Skip to main content

Breadcrumb

  1. Home

Leveraging personalized circulating tumor DNA (ctDNA) for detection and monitoring of molecular residual disease in high-risk melanoma

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about Leveraging personalized circulating tumor DNA (ctDNA) for detection and monitoring of molecular residual disease in high-risk melanoma

Preliminary results of the Liquid Biopsy for Minimal Residual Disease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS) study

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about Preliminary results of the Liquid Biopsy for Minimal Residual Disease Detection in Head and Neck Squamous Cell Carcinoma (LIONESS) study

PAK4 as a potential marker for poor response to immunotherapy in melanoma patients

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about PAK4 as a potential marker for poor response to immunotherapy in melanoma patients

Updated follow-up data and biomarker analysis of pre-operative ipilimumab and nivolumab in locoregional advanced urothelial cancer (NABUCCO)

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about Updated follow-up data and biomarker analysis of pre-operative ipilimumab and nivolumab in locoregional advanced urothelial cancer (NABUCCO)

Liquid biopsy for detection of molecular residual disease and recurrence in head and neck squamous cell carcinoma

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about Liquid biopsy for detection of molecular residual disease and recurrence in head and neck squamous cell carcinoma

A single-tube NGS assay for simultaneous detection of DNA and RNA biomarkers as a comprehensive solution for clinical management and guiding therapeutic intervention of Ph-like ALL patients

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about A single-tube NGS assay for simultaneous detection of DNA and RNA biomarkers as a comprehensive solution for clinical management and guiding therapeutic intervention of Ph-like ALL patients

Deep phenotyping and spatial immune contexture characterization through a combined multiplex immunofluorescence ( mIF ) approach

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about Deep phenotyping and spatial immune contexture characterization through a combined multiplex immunofluorescence ( mIF ) approach

Comparison of a personalized sequencing assay and digital PCR for circulating tumor DNA based Molecular Residual Disease detection in early-stage triple negative breast cancer in the cTRAK-TN trial.

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about Comparison of a personalized sequencing assay and digital PCR for circulating tumor DNA based Molecular Residual Disease detection in early-stage triple negative breast cancer in the cTRAK-TN trial.

Circulating Tumour DNA (ctDNA) Detection and Dynamics in Patients with Early Breast Cancer (EBC): Results of the Neoadjuvant TRACER cohort

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about Circulating Tumour DNA (ctDNA) Detection and Dynamics in Patients with Early Breast Cancer (EBC): Results of the Neoadjuvant TRACER cohort

NGS assay for simultaneous screening of DNA and RNA provides a comprehensive solution guiding clinical management of ALL patients

Submitted by Anonymous (not verified) on Mon, 12/23/2024 - 06:53
  • Read more about NGS assay for simultaneous screening of DNA and RNA provides a comprehensive solution guiding clinical management of ALL patients

Pagination

  • First page First
  • Previous page Previous
  • …
  • Page 13
  • Page 14
  • Page 15
  • Page 16
  • Page 17
  • Page 18
  • Page 19
  • Page 20
  • Page 21
  • …
  • Next page Next
  • Last page Last
Subscribe to